Palisade Bio (NASDAQ:PALI – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($2.32) earnings per share for the quarter, beating the consensus estimate of ($3.35) by $1.03, Zacks reports.
Palisade Bio Stock Performance
PALI stock opened at $2.62 on Friday. The business has a fifty day simple moving average of $3.35 and a 200-day simple moving average of $4.20. Palisade Bio has a 52 week low of $2.18 and a 52 week high of $22.35.
Wall Street Analyst Weigh In
Separately, Maxim Group decreased their price target on Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday.
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
Featured Articles
- Five stocks we like better than Palisade Bio
- Best Stocks Under $10.00
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- What Are Dividends? Buy the Best Dividend Stocks
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- Bank Stocks – Best Bank Stocks to Invest In
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
